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Background: Tumor necrosis factor- (TNF-) has been implicated in the blood vessel wall response to hemodynamic
forces. We hypothesized that TNF- activity drives neointimal hyperplasia (NIH) during vein graft arterialization and
that anti-TNF- therapy would inhibit NIH.
Methods: Rabbits underwent bilateral vein grafting using jugular vein. All distal branches except the occipital artery were
unilaterally ligated to create distinct flow environments between the bilateral grafts. Vein grafts were harvested
sequentially up to 28 days for TNF- messenger RNA (mRNA) quantitation. In separate experiments, animals received
short-term or long-term dosing with pegylated soluble TNF- type I receptor (PEG sTNF-RI) or vehicle. After 14 to 28
days, grafts were analyzed for morphometry, proliferation, apoptosis, and PEG sTNF-RI distribution.
Results: Quantitative mRNA assay (TaqMan) revealed shear-dependent (P < .001) and time-dependent (P < .001)
TNF- expression. TNF- induction was maximal at day 1 and gradually decreased over time, but was persistently
elevated even 4 weeks later (P< .001). Low shear (associated with increased NIH) resulted in significantly higher TNF-
mRNA expression (P  .03). PEG sTNF-RI was found in high concentrations in the serum and localized to NIH. The
high-flow and low-flow vein grafts from treated animals demonstrated similar volumes of NIH compared with controls.
PEG-sTNF-RI had only modest impact on vascular wall cell turnover, as reflected by terminal deoxynucleotide
transferase-mediated deoxy uridine triphosphate nick-end labeling (P  .064) and anti-Ki-67 (P  .12) assays.
Conclusions: Placement of a vein into the arterial circulation acutely upregulates TNF-; this expression level correlates
with the degree of subsequent NIH. Pharmacologic interruption of this signaling pathway has no significant impact on
NIH or wall cellular proliferation/apoptosis, suggesting that early vein graft adaptations can proceed via TNF-–
independent mechanisms. (J Vasc Surg 2007;45:169-76.)
Clinical Relevance:Neointimal hyperplasia stands as a fundamental pathology of vein graft failure. This study reveals that
low wall shear significantly upregulates early and acute proinflammatory cytokine tumor necrosis factor- (TNF-) in
vein grafts (with robust neointimal formation), whereas high wall shear is associated with less TNF- induction and
neointimal hyperplasia. Further studies demonstrate that blockage of inflammatory TNF- signaling fails to abrogate
occlusive vein graft lesions. Thus, further research is required to delineate the biologic significance of the TNF-
expression dynamics observed in the early vein graft.Autologous vein remains the preferred conduit for
surgical bypass constructions. However, approximately
20% of the grafts fail early because of neointimal hyperpla-
sia,1 a lesion characterized by uncontrolled cell prolifera-
tion and extracellular matrix deposition. Although the cel-
lular events and molecular mechanisms responsible for this
process have not been fully elucidated, inflammatory mech-
anisms have been proposed.2 The recruitment and activa-
tion of inflammatory cells results in local accumulation of
cytokines, chemokines, growth factors, proteases, and
other bioactive substances, which in turn, drive cell differ-
entiation, proliferation and migration, and matrix deposi-
tion.3 These events can lead to clinically advantageous
adaptations that remodel the vein graft wall to accommo-
date the relatively higher pressure and flow burden, but
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luminal narrowing and graft failure.
Proinflammatory cytokines, such as tumor necrosis
factor- (TNF-) have been associated with neointimal
hyperplasia in vein grafts.4-6 TNF- is a pleiotropic cyto-
kine that holds many properties implicated in neointimal
hyperplasia and wall remodeling. For example, it induces
production of inflammatory mediators such as intracellular
adhesion molecule-1,7 monocyte chemotactic protein-1,
and growth factors,8 stimulates smooth muscle cell and
fibroblast proliferation and migration,9 and promotes ma-
trix degradation,10 and thus facilitates reorganization of
vascular structure.
We have demonstrated in vivo that TNF- drives arte-
rial neointimal hyperplasia induced by low wall shear11 as
well as the vascular reorganization associated with arterio-
genesis.12,13 Genetic interruption of p55-initiated TNF-
signaling has successfully abrogated neointimal hyperplasia
in murine vein grafts.14 The established pharmacologic
anti-TNF- therapies for rheumatoid arthritis15 and in-
flammatory bowel disease16 provide tools to further dissect
inflammatory mechanisms and offer the potential for rapid
clinical translation.
The purpose of the current study was to define the
temporal expression pattern of TNF- in vein grafts with
both high and low wall shear and then use this knowledge
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occlusive vein graft adaptations. We hypothesized that (1)
TNF- signaling is temporally defined and drives neointi-
mal hyperplasia during vein graft arterialization, and that
(2) appropriately timed pharmacologic anti-TNF- therapy
would localize to the early vein graft wall and inhibit vein
graft neointimal hyperplasia. To add to the experimental
robustness and explore potential mechanisms, we tested
these hypotheses in both high and low wall shear grafts
created in the same animal.
METHODS
Rabbit vein graft model, including both high and
low wall shear grafts. This study conforms to the Amer-
ican Physiological Society’s Guiding Principles in the Care
and Use of Animals, and the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, revised
1996). Male New Zealand White rabbits (3.0 to 3.5 kg)
underwent bilateral jugular vein interposition grafting, fol-
lowed by immediate unilateral distal carotid artery branch
ligation to create two distinct flow environments within the
same animal.17
Rabbits were premedicated with ketamine (30 mg/kg
intramuscularly), intubated, and anesthetized with inhaled
isoflurane. Intravenous heparin (1000 units) was adminis-
tered, and bilateral external jugular veins and common
carotid arteries were exposed through a vertical midline
cervical incision. Vein bypass grafts were constructed using
an anastomotic cuff technique.17 Briefly, bilateral external
jugular veins were harvested (3 cm in length). Polymer cuffs
consisting of a 1-mm body loop were fashioned from a 4F
endovascular catheter (Terumo Medical Corp, Elkton,
Md). Jugular vein ends were passed through a cuff, everted,
and fixed using 8-0 silk. The carotid artery lumen was then
exposed using a 2-cm arteriotomy, and the cuffed, reversed
vein ends were inserted. A second 8-0 silk was used to
secure the artery around the cuff. Finally, 1.0 cm of carotid
artery back wall between the cuffs was excised to permit
vein graft extension. Unilateral reduction in vein graft flow
was accomplished by placement of 8-0 silk suture ligatures
to completely occlude all branches except the occipital
artery (Fig 1).
TNF- mRNA quantification in the early vein
graft. Five animals for each time point were euthanized
at 1, 3, 7, 14, and 28 days. Four normal and unmanipu-
lated jugular veins were harvested from separate animals
and served as time 0 baseline controls. High-resolution
video images were obtained both at graft placement and
harvest and used to determine external graft dimensions.
Mean blood flow rate was recorded using an ultrasonic
flow meter with a 2.0-mm T106 probe (Transonic Sys-
tems, Ithaca, NY).
Specimens were frozen immediately in liquid nitrogen
or immersed in 10% neutral buffered formalin for histologic
analysis. Morphologic analyses were completed using both
in vivo external graft diameter and cross-sectional measure-
ments (AxioVision 3.1, Carl Zeiss MicroImaging, Göttin-
gen, Germany) on Masson and van Gieson’s elastin stainedspecimens, as detailed in our previous report.17 Briefly,
digitized in vivo digital video and fixed microscopic cross-
sectional images were collected and analyzed to determine
the lumen diameter (DL) and neointimal cross-sectional
area (Ai) for each specimen. Wall shear stress was estimated
using Poiseuille’s law (  32Q/DL
3), where Q is the
mean flow rate and  is the viscosity (0.03 poise). Neoin-
timal thickness (Ti) was approximated by [Ti 2Ai/(PL
PIEL)], where PL is the perimeter of the lumen and PIEL is
the internal elastic lamina.
Quantitative real-time two-step polymerase chain re-
action (RT-PCR) was performed on paired vein grafts.
Total RNA was isolated using TRI and 1-bromo-3-
chloropropane (BCP) phase-separation reagents (Mo-
lecular Research Center, Cincinnati, Ohio) according to
the manufacture’s protocol. After treatment with DNase
I (Ambion, Austin, TX), reverse transcription was com-
plete using random hexamers (PE Applied Biosystems,
Foster City, Calif) to obtain a final complimentary DNA
(cDNA) concentration of 20 ng/L.
RT-PCR for TNF- (forward primer, AGGAAGAGTC-
CCCAAACAACCT; reverse primer, GGCCCGAGAAGC-
TGA TCTG; probe, AGTCAACCCTGTGGCCCAGAT-
GGTC) was performed on a PE 7700 Sequence Detection
System (PE Applied Biosystems) by using 200 nM forward
primer, 200 nM reverse primer, 50 nM probe, and 10 ng
Fig 1. Bilateral vein graft model with differential flow environ-
ments. Left panel, External jugular vein interposition in the
common carotid artery was constructed with cuffed anastomosis.
Right panel, All distal branches except the occipital artery were
ligated to decrease the ipsilateral flow and gain compensatory
increase in the blood flow on the opposite side. Adapted from
Am J Physiol Heart Circ Physiol 2004;286:H240-5. Used with
permission.cDNA per 25 mL reaction volume, and TaqMan Universal
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simultaneously run for 18S RNA on all individual samples
as an internal control. Samples and controls were assayed in
triplicate. The Comparative Ct Method18 was used for
experiments and data analysis. Results are expressed as
relative mRNA expression after normalization to 18S ribo-
somal RNA to minimize variability from sample loading,
and finally, calibrated to unmanipulated jugular vein.
TNF inhibition experiments. Pegylated soluble hu-
man TNF type I receptor (PEG sTNF-RI; Amgen Inc,
Thousand Oaks, Calif), a 20-kd molecule containing a
homodimer of human p55 covalently linked to a poly-
ethylene glycol backbone,19 was used to inhibit soluble
TNF- binding to receptors. Molecular modification of
these pegylated receptors, through deletion of 1.4 intra-
cellular domains, serve to reduce immunogenicity while
having no impact on ligand binding.20 Owing to a
conserved sequence homology, the compound has been
demonstrated to abrogate the adaptive immune response
across a range of species, including the rabbit.19,21 Par-
ticularly, Porat et al21 showed that human p55 is able to
recognize and bind to rabbit TNF- and functionally
block rabbit TNF- bioactivity. In a rabbit septic shock
model induced by Escherichia coli infusion, recombinant
human p55 significantly reduced TNF- bioactivity in
the serum and successfully saved the animals’ lives, with
a survival rate of 100% for treated group and 55.6% for
saline control.21
Based on the TNF- expression results, two anti-
TNF- treatment strategies were used. First, an intense
short-term course to block the early, immediate effects of
TNF on vein graft adaptation was followed by examina-
tion of the morphology at 28 days. And second, a
longer-term intervention, designed to explore the im-
pact of prolonged TNF- inhibition, was initiated pre-
operatively and continued for the entire 14-day implan-
tation period. Vein grafts were constructed as described
earlier, using the high and low shear conditions to exam-
ine for potential flow-dependent effects of the inhibitors.
Animals were assigned by randomized block design and
subcutaneously dosed with either PEG sTNF-RI (10
mg/kg daily) or the same volume of phosphate-buffered
saline (PBS) (Table). At harvest, vein grafts were perfu-
sion-fixed in situ with 4% formalin. The middle portion
of the graft was processed for morphologic, immunohis-







time (day)Treatment Control Pre-op Post-op
Short-term 6 5 0 5 28
Long-term 8 8 1 14 14
*The treatment group received PEG sTNF-RI (10 mg/kg daily) subcuta-
neously; controls received the same volume of phosphate-buffered saline.tochemical, and terminal deoxynucleotide transferase-mediated deoxy uridine triphosphate nick-end labeling
(TUNEL) analysis.
Immunohistochemical and TUNEL Analyses.
Formalin-fixed sections were rehydrated and treated
with antigen retrieval solution (Cat. S2369, Dako,
Glostrup, Denmark). Ki-67, a nuclear protein expressed
by proliferating cells, was assayed for cell proliferation.
Sections were incubated with mouse anti-rat Ki-6713
(clone MIB-5, 1:400; Dako) at 4°C overnight, then with
biotin conjugated goat anti-mouse (Cat M32115,
CALTAG Laboratory/Invitrogen, Carlsbad, Calif) at
room temperature for 1 hour. Avidin: biotinylated en-
zyme complex (ABC) and 3,3’-diaminobenzidine
(DAB) kits (Vector, Burlingame, Calif) were applied to
visualize the specific staining, with hematoxylin counter-
stain. Anti-PEG sTNF-RI immunostaining was per-
formed in a similar manner to Ki-67, except antigen
retrieval and incubation with secondary antibody were
omitted. Rabbit anti-PEG sTNF-RI was provided by
Amgen and labeled with biotin (Cat 21335, Pierce Bio-
technology, Rockford, Ill). Substitution of antibody di-
lution serum for the primary antibodies served as a
negative control. TUNEL assay was performed using an
in situ cell death detection kit (Cat 11 684 809 910,
Roche Diagnostics, Indianapolis, Ind) and propidium
iodide (PI) counterstain. Images were analyzed under
confocal. Two individuals blinded to the study counted
positively stained cells in two sections for each vein graft.
Confirmation of PEG sTNF-RI localization to the
early vein graft. Protein extraction from frozen specimens
was performed in 0.05 M Tris (pH 7.5) and 0.2% Triton
X-100 using a mortar and pestle. A human sTNF-RI
enzyme-linked immunosorbent assay (ELISA) kit (R&D,
Minneapolis, MN) was used to determine PEG sTNF-RI
content.
Statistical analysis. The effects of time and wall shear
were evaluated statistically using two-way repeated mea-
sures analysis of variance. Unpaired t tests were performed
to determine the statistical significance between treatment
groups and controls. Results are expressed as the mean 
SEM.
RESULTS
Rabbit model of high and low wall shear vein
grafts. Consistent with previous publications using this
model,17 an immediate 11-fold differential in wall shear
between high-flow and low-flow grafts was created and
maintained during the initial 14 days after implantation
(Fig 2, A ). Secondary to outward remodeling and a
compensatory increase in luminal diameter, at 28-days
the high shear grafts returned to baseline values. The
morphologic impact was an accelerated development of
intimal hyperplasia in grafts exposed to the low-flow
simulation (Fig 2, B ).
TNF- mRNA quantification. RT-PCR for TNF-
revealed shear-dependent (P  .001) and time-dependent
(P  .001) cytokine expression signatures (Fig 2, C).
TNF- was induced 142-fold and 94-fold in low and high
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day. This elevation gradually decreased over time but was
persistently elevated from baseline with 25-fold and 17-fold
induction for low and high shear vein grafts, respectively, at
the 28-day time point (P  .001). Over the course of the
study, low shear (associated with increased wall intimal
hyperplasia) resulted in significantly higher TNF- mRNA
(P  .03) vein graft wall expression.
Anti-TNF- intervention. None of the PEG sTNF-
RI–treated animals exhibited clinically detectable side ef-
fects or complications as measured by body temperature,
change in weight, and feeding. However, small superficial
Fig 2. A, Shear stress, B development of neointima, and C ex-
pression of tumor necrosis factor- (TNF-) messenger RNA
(mRNA) in low-flow and high-flow vein grafts over time. Both
time and flow were identified as independent factors by two-way
repeated measures analysis of variance (P  .001 for all three end
points). Data are presented as means  SEM.skin ulcers associated with the neck incision occurred in twolong-term PEG–sTNF-RI–treated animals, and these were
present at the time of harvest.
Long-term administration of PEG sTNF-RI resulted
in a high accumulation of the compound in the plasma
and vascular tissues (97.5 2.3 g/mL in plasma, 0.52
0.08 pg/g total protein in inferior vena cava, and 0.08
0.01 pg/g total protein in carotid artery). Immunohisto-
chemistry revealed that PEG sTNF-RI was largely localized
to the cells in developing neointima (Fig 3).
Flow measurements confirmed both treated and vehi-
cle control groups were exposed to similar initial flow
conditions (Fig 4). Compared with vehicle administration,
short-term or long-term treatment failed to influence neo-
intimal thickness or internal elastic lamina length in either
low or high shear grafts (Fig 4). Qualitatively the morphol-
ogy among all the groups was indistinguishable.
There was a tendency for a higher density of TUNEL
(P .064) and a lower density of Ki-67–positive cells (P
.12) within the neointima of the group with long-term
PEG sTNF-RI treatment compared with controls, whereas
an equivalent number of cells positive for TUNEL and
Ki-67 were detected within the reminder of the graft wall
(media plus adventitia) for both treated and control groups
(Fig 5).
DISCUSSION
It has been observed that blood vessels develop occlu-
sive vascular lesions and remodel in response to disordered
flow and low wall shear.22,23 Inflammatory mechanisms
drive this blood vessel wall response.3 Few situations in
biology result in a more dramatic perturbation of vessel wall
biomechanics than placement of a vein into the arterial
circulation; thus, the early vein graft offers an ideal and
clinically relevant system to dissect the biology of vascular
adaptations to biomechanical forces.
In support of existing paradigms, we demonstrated that
low wall shear induced rapid, dramatic TNF- upregula-
tion in vein grafts that developed robust neointimal hyper-
plasia, whereas TNF- was more modestly elevated in high
wall shear grafts that formed minimal neointimal hyperpla-
sia.9,11,24 TNF- is a pleiotropic proinflammatory cytokine
that is able to stimulate the expression of other cytokines,
growth factors, and adhesion molecules, thus amplifying
the primary signal differentials25 and leading to the ampli-
fied biologic responses.
Consistent with this notion, our results demonstrate
that the magnitude of disparity in TNF- expression is
relatively less than that of neointimal hyperplasia. There
may not be direct biologic correlations with fold increases
in mRNA expression when baseline expression is low and
the increases are of such a large magnitude.
Although our immunohistology findings indirectly
support a neointimal cellular source for TNF-, direct
TNF- protein assays have been unsuccessful because of
overall low protein accumulation. It is widely accepted that
cytokine mRNA levels generally reflect the overall biologic
activity of these compounds. The time course demonstrat-
ing maximal induction 1 day after implantation closely
ecific
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1	.6
The delineation of this early temporal therapeutic
“window of opportunity,” along with several lines of exist-
ing evidence,14 suggested that systemic anti-TNF therapy
could be used to inhibit neointimal hyperplasia in the vein
Fig 3. Left panel, Pegylated soluble tumor necrosis
long-term treated graft (no counterstain). PEG sTNF-R
internal elastic lamina. Right panel,Negative control (w
was completely negative, suggesting the specificity of an
benzidine precipitation was employed to visualize the sp
Fig 4. Summary of flow rate at the time of harvest, neointimal
thickness, and internal elastic lamina (IEL) length for vein grafts
with short-term (daily dosing for the first 5 postoperative days
of a 28-day observation period) and long-term (daily dosing
from 1 day preoperatively until the end of the 14-day observa-
tion) anti-tumor necrosis factor- treatment. No significant
difference was detected for both low-flow and high-flow grafts
between treated vein grafts and vehicle controls. PEG sTNF-RI,
Pegylated soluble tumor necrosis factor receptor 1. Data are
presented as means  SEM.graft. Previous studies in our laboratory demonstrated thatless arterial neointima developed in mice deficient in
TNF-when they were exposed to decreased shear, and the
reduction was most likely attributed to the soluble TNF
ligand.11 Further studies by Zimmerman et al26 extended
and confirmed these findings. They reported that TNF-
promoted arterial injury–induced neointimal hyperplasia
through the type I receptor (p55).26
Multiple factors must be considered in light of such
high early expression, yet no perceivable biologic effect
with TNF- signaling inhibition. Certainly possible is that
neointimal hyperplasia in this specific setting can proceed
independent of TNF- signaling or via compensatory
mechanisms. Also, limitations in the rabbit model used in
this study may result in a false-negative observation. The
cuffed anastomosis we used results in compliance mismatch
and does not mimic a sutured anastomosis. Thus, we dis-
carded about 3 mm graft near each cuffed anastomosis.
Although we model mid vein graft neointimal hyperplasia,
the current study does not explore the biology of anasto-
motic events directly. The surgery involved with vein graft
placement, presence of skin ulcers, and possibly low-grade
cerebral ischemia may all result in systemic soluble TNF-
release that may impact the local vein graft wall environ-
ment.
Despite high dosages, PEG sTNF-RI binding to the
soluble and membrane-bound TNF- may have been in-
complete. However, our dosage (10 mg/kg) was twice as
much as the effective dosage (5 mg/kg) for the treatment
of rabbit sepsis,21 and our mean plasma concentration of
PEG sTNF-RI was 97  3 g/mL, which is far above the
concentration (5 g/mL) at which the maximum effects
for treatment of rheumatoid arthritis was achieved.27 As
shown in Fig 3, this drug is able to penetrate into the vein
graft wall, and the cellular colocalization with the neoin-
tima suggests that neointimal cells accumulate TNF-,
which is then recognized and bound by PEG sTNF-RI.
Our results do not provide absolute confirmation that the
decoy effectively abrogates a biologically significant per-
centage of TNF- signaling in rabbits for the vein graft
scenario. It is possible that other anti-TNF- approaches,
such as infliximab or etanercept, would offer pharmaco-
r receptor I (PEG sTNF-RI) immunoreactivity in a
calizes with cells in the neointima. Arrowheads indicate
he antibody was replaced with antibody dilution serum)
G sTNF-RI immunostaining. Enzymatic 3,3’-diamino-




ti-PElogic advantages that would demonstrate clinical benefit.
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that a “catch up” phenomenon may be taking place.28,29
However, data from the long-term blockage experiment
further supports the observation that PEG sTNF-RI did
not significantly impact neointimal hyperplasia and remod-
eling.
Neointimal hyperplasia in the adapting vein graft offers
some structural compensation so that the conduit is able to
accommodate the pulsatile arterial blood flow under high
pressure and wall shear. Although this adaptation facilitates
its function in an arterial environment, the neointima may
also serve as a fertile soil for the development of other
vascular lesions such as atherosclerosis.30 An effect of anti-
TNF therapy could be a shifting of biologic properties of
the neointima away from a proatheromatous phenotype.
However, neointima in both PEG sTNF-RI–treated and
vehicle-treated grafts demonstrated a similar response with
respect to cell apoptosis, proliferation, and qualitative
structural organization, although long-term end points
were not examined.
Although the current findings indirectly conflict with
some work from other groups, they probably more realis-
tically point to a sophisticated biology for TNF- and its
pharmacologic blockage in vivo. Zhang et al14 reported
that blocking TNF- signaling via p55 deletion inhibited
neointimal hyperplasia in mouse vein grafts by 40%, and
this neointimal attenuation was primarily attributed to
graft-intrinsic TNF- signaling. Their work clearly demon-
strated that in the mouse model, TNF- signaling pro-
Fig 5. Upper panel, Density of TUNEL (A) and Ki-6
antitumor necrosis factor- treatment. Data are presente
TUNEL and Ki-67 from the same animal. The treated
Ki-67–positive cells in the neointima, but these differen
soluble tumor necrosis factor receptor 1; TUNEL, te
triphosphate nick-end labeling.motes vein graft neointimal hyperplasia.In support of this concept is the finding that blocking
TNF- signaling by soluble p75-immunoglobulin G fusion
protein (etanercept) resulted in accelerated endothelial cell
recovery and reduction of neointimal hyperplasia induced
by arterial injury.31 In our experiment, however, PEG
sTNF-RI serves as a decoy to TNF- ligand; therefore,
treatment with PEG sTNF-RI probably substantially de-
creases (rather than fully abrogates) the binding of TNF-
to the endogenous receptors.
Differential responses to anti-TNF- therapies in vari-
ous disease settings have also been noted, although the role
TNF- is considered to be essential in the pathogenesis of
the lesions. For example, administration of etanercept, a
modified TNF-RII, brought little benefits to patients with
Crohn disease,32 whereas the same dosing regimen led to
significant reductions in arthritis activity.33 Anti-TNF-
therapy can be achieved at different levels of the TNF-
signaling cascade, and several anti-TNF bioactivity reagents
have therefore been developed for clinical trials or disease
treatment, or both.34
Little is known about the impacts of anti-TNF therapy
on vein graft neointimal hyperplasia, but a few studies have
examined different anti-TNF approaches (soluble recep-
tor35 and anti-TNF antibody36) in rabbit arterial neointi-
mal hyperplasia. The outcomes hold potential controversy,
however. Among the confounding factors are the unique
receptor kinetics of TNF-, where incomplete TNF block-
age under low TNF- concentration has been observed
) positive cells in low-flow vein grafts with long-term
means  SEM. Lower panel, Representative images for
grafts tended to have more TUNEL-positive and less
re not statistically significant. PEG sTNF-R1, Pegylated




rminaowing to the endogenous p75 recruitment of TNF- and
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p55.37
CONCLUSION
Placement of a vein into the arterial system acutely
induces TNF- expression, with an early peak at 24 hours
and a lower but sustained expression lasting weeks. This
induction is modulated by wall shear stress, with marked
augmentation of TNF- under low shear, which is associ-
ated with accelerated neointimal hyperplasia. Based on the
PEG sTNF-RI treatment experiments, however, vein graft
wall adaptations such as neointimal hyperplasia can proceed
independent of TNF- signaling.
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